References
- Pelechas E, Voulgari PV, Drosos AA. Recent advances in the opioid mu receptor based pharmacotherapy for rheumatoid arthritis. Expert Opin Pharmacother. 2020;21(17):2153–60. doi:https://doi.org/10.1080/14656566.2020.1796969.
- Day AL, Curtis JR. Opioid use in rheumatoid arthritis: trends, efficacy, safety, and best practices. Curr Opin Rheumatol. 2019;31(3):264–70. doi:https://doi.org/10.1097/BOR.0000000000000602.
- Cao Y, Fan D, Yin Y. Pain mechanism in rheumatoid arthritis: from cytokines to central sensitization. Mediators Inflamm. 2020;2020:2076328. doi:https://doi.org/10.1155/2020/2076328.
- Fernández-Ávila DG, Rincón-Riaño DN, Bernal-Macías S, Gutiérrez Dávila JM, Rosselli D. Prevalence of rheumatoid arthritis in Colombia based on information from the Ministry of Health registry. Rev Colomb Reumatol. 2019;26(2):83–7. doi:https://doi.org/10.1016/j.rcreue.2019.01.009.
- Sparks JA. In the Clinic® rheumatoid arthritis. Ann Intern Med. 2019;170(1):ITC1–15. doi:https://doi.org/10.7326/AITC201901010.
- Safiri S, Kolahi AA, Hoy D, Smith E, Bettampadi D, Mansournia MA, Almasi-Hashiani A, Ashrafi-Asgarabad A, Moradi-Lakeh M, Qorbani M, et al. Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis. 2019;78(11):1463–71. doi:https://doi.org/10.1136/annrheumdis-2019-215920.
- Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. Nat Rev Dis Prim. 2018;4:1–23. doi:https://doi.org/10.1038/nrdp.2018.1.
- Norteamericano C. Guía de Práctica Clínica : Nuevos criterios para el diagnóstico temprano de la artritis reumatoide. New diagnostic classification for rheumatoid arthritis. Ann Rheum Dis. 2010;69:1580–1588.
- Chico Capote A, Hernán Estévez del Toro M, León Gutiérrez E, Gutiérrez Rojas A. Valoración de un método de evaluación de la actividad en la artritis reumatoide para la práctica clínica. Acta Médica. 2019;20(1). Recuperado de. http://www.revactamedica.sld.cu/index.php/act/article/view/10.
- Walsh DA, Mcwilliams DF. Pain in rheumatoid arthritis. Curr Pain Headache Rep. 2012;16:509–17. doi:https://doi.org/10.1007/s11916-012-0303-x.
- Hukkanen M, Salo J. Innervation of the joint and role of neuropeptides. Ann N Y Acad Sci. 2006;1069:149–54.
- Hong JI, Park IY, Kim HA. Understanding the molecular mechanisms underlying the pathogenesis of arthritis pain using animal models. Int J Mol Sci. 2020;21(2):533. doi:https://doi.org/10.3390/ijms21020533.
- Whittle SL, Richards BL, Husni E, Buchbinder R. Opioid therapy for treating rheumatoid arthritis pain. Cochrane Database Syst Rev. 2011;(11):CD003113. doi:https://doi.org/10.1002/14651858.CD003113.pub3.
- Bullock J, Rizvi SAA, Saleh AM, Ahmed SS, Do DP, Ansari RA, Ahmed J. Rheumatoid arthritis: a brief overview of the treatment. Med Princ Pract. 2018;27(6):501–7. doi:https://doi.org/10.1159/000493390.
- Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685–99.
- Guipcar G. Guía de Práctica Clínica para el Manejo de Pacientes con Artritis Reumatoide. Soc Española Reumatol. 2018;2(7):46–69.
- Alejandro BC, Petra F. Manejo de Pacientes con Artritis Reumatoide para el [Internet]. Sociedad Española de Reumatología. 2019. [accessed July 15] p. 1–70. https://www.ser.es/wp-content/uploads/2019/03/Guia-de-Practica-Clinica-para-el-Manejo-de-Pacientes-con-Artritis-Reumatoide.pdf.
- Malmström V, Catrina AI, Klareskog L. The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting. Nat Rev Immunol. 2017;17(1):60–75. doi:https://doi.org/10.1038/nri.2016.124.
- Moore MN, Wallace BI. Glucocorticoid and opioid use in rheumatoid arthritis management. Curr Opin Rheumatol. 2021;33:277–83.
- Hua C, Buttgereit F, Combe B. Glucocorticoids in rheumatoid arthritis: current status and future studies. RMD Open. 2020;6:e000536.
- Yao T, Huang Y, Chang S, Tsai S, Wu AC. Association between oral corticosteroid bursts and severe adverse events. Ann Intern Med. 2020;173(5):325–330.
- Waljee AK, Rogers MAM, Lin P, Singal AG, Stein JD, Marks RM, et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. 2017;357:j1415.
- Geenen R, Overman CL, Christensen R, Åsenlöf P, Capela S, Huisinga KL, Husebø MEP, Köke AJA, Paskins Z, Pitsillidou IA, et al. EULAR recommendations for the health professional’s approach to pain management in inflammatory arthritis and osteoarthritis. Ann Rheum Dis. 2018;77(6):797–807. doi:https://doi.org/10.1136/annrheumdis-2017-212662.
- National Institue for Health and Clinical Excellence Guideline. Rheumatoid arthritis in adults: management. NICE Clinical Guideline. 2018 [accessed July 18];1–31. https://pathways.nice.org.uk/pathways/rheumatoid-arthritis#path=view%3A/pathways/rheumatoid-arthritis/drug-treatment-for-rheumatoid-arthritis.xml&content=view-index.
- Nissen SE, Yeomans ND, Solomon DH, Lüscher TF, Libby P, Husni ME, Graham DY, Borer JS, Wisniewski LM, Wolski KE, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016;375(26):2519–29. doi:https://doi.org/10.1056/NEJMoa1611593.
- National Institute for Health and Care Excellence (NICE). Rheumatoid arthritis in adults: diagnosis and management—evidence review G Analgesics [Internet]; 2018 [accessed July 20]. https://www.nice.org.uk/guidance/ng100/evidence/evidence-review-g-analgesics-pdf-4903172324.
- Garner SE, Fidan D, Frankish RR, Judd M, Shea B, Towheed T, et al. Celecoxib for rheumatoid arthritis. Cochrane Database Syst Rev. 2002;(4):CD003831. doi:https://doi.org/10.1002/14651858.CD003831.
- Lee YC, Kremer J, Guan H, Greenberg J, Solomon DH. Chronic opioid use in rheumatoid arthritis: prevalence and predictors. Arthritis Rheumatol. 2019;71(5):670–7. doi:https://doi.org/10.1002/art.40789.
- Kim SC, Solomon DH. Towards defining the safer use of opioids in rheumatology. Nat Rev Rheumatol. 2020;16(2):71–2. doi:https://doi.org/10.1038/s41584-019-0360-1.
- Zamora-Legoff JA, Achenbach SJ, Crowson CS, Krause ML, Davis JM, Matteson EL. Opioid use in patients with rheumatoid arthritis 2005-2014: a population-based comparative study. Clin Rheumatol. 2016;35(5):1137–44. doi:https://doi.org/10.1007/s10067-016-3239-4.
- Boytsov NN, Bhattacharya R, Saverno K, Dixon L, Abbott PL, Zhang X, Gaich CL, Nair R. Health care effect of disease-modifying antirheumatic drug use on patients with rheumatoid arthritis. JMCP. 2019;25(8):879–87. doi:https://doi.org/10.18553/jmcp.2019.25.8.879.
- Kimsey L, Weissman JS, Patel A, Drew A, Koehlmoos T, Sparks JA. Delay in initiation of DMARD or anti-inflammatory therapy in patients newly diagnosed with rheumatoid arthritis: an analysis of United States Military Health System TRICARE beneficiaries. Semin Arthritis Rheum. 2019;48(5):821–7. doi:https://doi.org/10.1016/j.semarthrit.2018.07.003.
- Noori SA, Aiyer R, Yu J, White RS, Mehta N, Gulati A. Nonopioid versus opioid agents for chronic neuropathic pain, rheumatoid arthritis pain, cancer pain and low back pain. Pain Manag. 2019;9(2):205–16. doi:https://doi.org/10.2217/pmt-2018-0052.
- Ramiro S, Radner H, Van Der Heijde DM, Buchbinder R, Aletaha D, Landewé RB. Combination therapy for pain management in inflammatory arthritis: a cochrane systematic review. J Rheumatol Suppl. 2012;90(39):47–55. doi:https://doi.org/10.3899/jrheum.120342.
- Sundar S. Efficacy and safety profile of combination of tramadol-diclofenac versus tramadol-paracetamol in patients with acute musculoskeletal conditions, postoperative pain, and acute flare of osteoarthritis and rheumatoid arthritis: a phase III, 5-day open-label study. J Pain Res. 2014;7:455–63.
- Richards BL, Whittle SL, Buchbinder R. Neuromodulators for pain management in rheumatoid arthritis. Cochrane Database Syst Rev. 2012;1(1):CD008921. doi:https://doi.org/10.1002/14651858.CD008921.pub2.
- Bl R, Sl W, Buchbinder R. Antidepressants for pain management in rheumatoid arthritis. J Pain Palliat Care Pharmacother. 2012;26(2):172.
- Richards BL, Whittle SL, Buchbinder R. Muscle relaxants for pain management in rheumatoid arthritis. Cochrane Database Syst Rev. 2012;1:CD008922. doi:https://doi.org/10.1002/14651858.CD008922.pub2.
- Guillouard M, Authier N, Pereira B, Soubrier M, Mathieu S. Cannabis use assessment and its impact on pain in rheumatologic diseases: a systematic review and meta-analysis. Rheumatology. 2021;60(2):549–56. doi:https://doi.org/10.1093/rheumatology/keaa534.
- Johal H, Devji T, Chang Y, Simone J, Vannabouathong C, Bhandari M. Cannabinoids in chronic non-cancer pain: a systematic review and meta-analysis. Clin Med Insights Arthritis Musculoskelet Disord. 2020;13:1179544120906461. doi:https://doi.org/10.1177/1179544120906461.
- IASP Presidential Task Force on Cannabis and Cannabinoid Analgesia. International Association for the Study of Pain Presidential Task Force on cannabis and cannabinoid analgesia position statement. Pain. 2021;162:S1–S2.
- Fisher E, Moore RA, Fogarty AE, Finn DP, Finnerup NB, Gilron I, Haroutounian S, Krane E, Rice ASC, Rowbotham M, et al. Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials. Pain. 2021;162(Suppl 1):S45–S66. doi:https://doi.org/10.1097/j.pain.0000000000001929.
- Moore RA, Fisher E, Finn DP, Finnerup NB, Gilron I, Haroutounian S, Krane E, Rice ASC, Rowbotham M, Wallace M, et al. Cannabinoids, cannabis, and cannabis-based medicines for pain management: an overview of systematic reviews. Pain. 2020;162(Suppl 1):S67–S79. doi:https://doi.org/10.1097/j.pain.0000000000001941.